Table 3.
Characteristic of patients treated with sorafenib
| Variable | Overall (n = 82) | BCLC stage B (n = 36) | BCLC stage C (n = 36) | BCLC stage D (n = 10) | P value |
| Age, yr (± SD) | 63 ± 9 | 63 ± 8 | 62 ± 10 | 63 ± 8 | 0.86 |
| Male gender, n (%) | 68 (82.9) | 29 (80.6) | 31 (86.1) | 8 (80.0) | 0.88 |
| Non-cirrhotic liver, n (%) | 9 (11.0) | 3 (8.3) | 5 (13.9) | 1 (10.0) | 0.78 |
| Etiology, n (%) | 0.11 | ||||
| HCV | 28 (34.1) | 16 (44.4) | 11 (30.6) | 1 (10.0) | |
| HBV | 4 (4.9) | 2 (5.6) | 1 (2.8) | 1 (10.0) | |
| Alcohol | 18 (21.9) | 9 (25.0) | 8 (22.2) | 1 (10.0) | |
| NASH | 10 (12.2) | 4 (11.1) | 4 (11.1) | 2 (20.0) | |
| Others | 22 (26.8) | 5 (13.9) | 12 (33.3) | 5 (50.0) | |
| Child Pugh A/B/C, n (%) | 48 (58)/30 (37)/4 (5) | 25 (69)/11 (31)/- | 21 (58)/15 (42)/- | 2 (20)/4 (40)/4 (40) | |
| CSPH1, n (%) | 45 (54.9) | 21 (58.3) | 18 (50.0) | 6 (60.0) | 0.66 |
| Median nº HCC nodules (IQR)2 | 2 (1-4) | 2 (2-4) | 2 (1-4) | 1.5 (1-2) | 0.25 |
| Median largest HCC diameter, mm, (IQR)2 | 70 (47-100) | 65 (46-90) | 87 (48.5-130) | 57.5 (39-121) | 0.56 |
| Bilobar involvement, n (%) | 30 (37.0) | 10 (27.8) | 18 (50.0) | 3 (30.0) | 0.33 |
| Diffuse HCC pattern, n (%) | 6 (7.4) | 2 (5.6) | 3 (8.3) | 1 (10.0) | 0.35 |
| Median AFP, ng/mL (IQR) | 103 (7.0-1069) | 30 (7.2-739) | 150 (6.3-1210) | 649 (16-2198) | 0.26 |
| AFP > 200 ng/mL, n (%) | 35 (43.7) | 12 (34.3) | 16 (45.7) | 7 (70) | 0.13 |
| AFP > 400 ng/mL, n (%) | 30 (37.5) | 10 (28.6) | 13 (37.1) | 7 (70) | 0.06 |
| AFP > 1000 ng/mL, n (%) | 21 (25.9) | 5 (14.3) | 12 (33.3) | 4 (40) | 0.13 |
| Vascular invasion, n (%) | 27 (33.3) | - | 25 (69.4) | 3 (30.0) | < 0.0001 |
| Extrahepatic disease, n (%) | 19 (23.5) | - | 18 (50.0) | 1 (10.0) | < 0.0001 |
1
Clinically significant portal hypertension defined as presence of at least one of the following: ascites, gastro-aesophagueal varices or hepatic encephalopathy.
2
Intrahepatic nodules. AFP: Alpha-feto protein; TACE: Transarterial chemoembolization; BCLC: Barcelona clinic liver cancer.